197 related articles for article (PubMed ID: 28948518)
1. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
[TBL] [Abstract][Full Text] [Related]
2. A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes.
Orzan F; Pagani F; Cominelli M; Triggiani L; Calza S; De Bacco F; Medicina D; Balzarini P; Panciani PP; Liserre R; Buglione M; Fontanella MM; Medico E; Galli R; Isella C; Boccaccio C; Poliani PL;
Lab Invest; 2020 Oct; 100(10):1330-1344. PubMed ID: 32404931
[TBL] [Abstract][Full Text] [Related]
3. Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Murata H; Yoshimoto K; Hatae R; Akagi Y; Mizoguchi M; Hata N; Kuga D; Nakamizo A; Amano T; Sayama T; Iihara K
J Neurooncol; 2015 Oct; 125(1):33-41. PubMed ID: 26272600
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity of glioblastomas: does location matter?
Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
[TBL] [Abstract][Full Text] [Related]
6. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
[TBL] [Abstract][Full Text] [Related]
7. RNA sequencing and Immunohistochemistry Reveal
Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
[TBL] [Abstract][Full Text] [Related]
8. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
Vasaikar S; Tsipras G; Landázuri N; Costa H; Wilhelmi V; Scicluna P; Cui HL; Mohammad AA; Davoudi B; Shang M; Ananthaseshan S; Strååt K; Stragliotto G; Rahbar A; Wong KT; Tegner J; Yaiw KC; Söderberg-Naucler C
BMC Cancer; 2018 Feb; 18(1):154. PubMed ID: 29409474
[TBL] [Abstract][Full Text] [Related]
10. MRI study identifies three subtypes of glioblastoma.
Brower V
Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
[No Abstract] [Full Text] [Related]
11. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Park J; Shim JK; Yoon SJ; Kim SH; Chang JH; Kang SG
Sci Rep; 2019 Jul; 9(1):10555. PubMed ID: 31332251
[TBL] [Abstract][Full Text] [Related]
12. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.
Marucci G; Morandi L; Magrini E; Farnedi A; Franceschi E; Miglio R; Calò D; Pession A; Foschini MP; Eusebi V
Virchows Arch; 2008 Dec; 453(6):599-609. PubMed ID: 18953566
[TBL] [Abstract][Full Text] [Related]
15. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
16. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
17. Normal tissue content impact on the GBM molecular classification.
Madurga R; García-Romero N; Jiménez B; Collazo A; Pérez-Rodríguez F; Hernández-Laín A; Fernández-Carballal C; Prat-Acín R; Zanin M; Menasalvas E; Ayuso-Sacido Á
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32632447
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme.
Yu X; Feng L; Liu D; Zhang L; Wu B; Jiang W; Han Z; Cheng S
Oncotarget; 2016 Mar; 7(12):14161-71. PubMed ID: 26895104
[TBL] [Abstract][Full Text] [Related]
19. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Zhang J; Xiao X; Zhang X; Hua W
J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
